Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-05
2006-09-05
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07101848
ABSTRACT:
The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of:(a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and(b) a second cyclic group which is formed by an amide bonding of an amino acid with the α-carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); andto the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.
REFERENCES:
patent: 4139526 (1979-02-01), Veber
patent: 6211145 (2001-04-01), Yanai et al.
Yano, et al., 1996, Bioorganic & Medicinal Chemistry, 4, 115-120.
Renner, et al., 1999, J. Am. Chem. Sco., 121, 11273-76.
He, et al., 1995, Bioorganic & Medicinal Chemistry, 5, 621-626.
Janice C. Parker, et al., “Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and Human Hepatocytes”, Diabetes, vol. 49, 2079-2086 Dec. 2000, XP-001154854.
James G. McCormack, et al., “Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy”, Current Pharmaceutical Design, 2001, 7, 1451-1474, XP-001154855.
K.F.Peterson, et al., “Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans”, Diabetologia (2001) 44:2018-2024, XP-002259423.
Mack Juergen
Maurer Till
Peters Stefan
Potterat Olivier
Streicher Ruediger
Boehringer Ingelheim Pharma GmbH & Co. KG
Campell Bruce R.
Devlin Mary-Ellen M.
Dow David A.
Gudibande Satyanarayana R.
LandOfFree
Bicyclic oligopeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic oligopeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic oligopeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525363